Reuters logo
BRIEF-Basilea Pharmaceutica - enters into agreement with Quintiles for commercialization of Zevtera/Mabelio in Europe
July 21, 2014 / 5:25 AM / 3 years ago

BRIEF-Basilea Pharmaceutica - enters into agreement with Quintiles for commercialization of Zevtera/Mabelio in Europe

July 21 (Reuters) - Basilea Pharmaceutica AG : * Says entered into agreement with Quintiles for commercialization of

Zevtera/Mabelio (ceftobiprole medocaril) in Europe * Says financial guidance for 2014 remains unchanged * Sees 2014 operating loss estimated at CHF 4 million to CHF 5 million per

month * Says 2014 total operating expenses estimated at CHF 8 million to CHF 9

million per month * Source text for Eikon [bit.ly/1jRlQTt] * Further company coverage

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below